| |||||||||||||||
| Approximately 85% of the compound mutant females develop focal mammary tumors at 6-10 months of age. Both virgin and breeder mice develop tumors. Approximately 37% of tumor-bearing mice develop metastatic disease to the lung. High expression of neu is detected in tumor tissue while very low levels are found in lung and ovary. Female mice carrying only the neuOT-I/OT-II mutation develop focal mammary tumors at approximately 18 months of age. | |||||||||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Former Names B6.FVB-Tg(MMTVneu-OT-I/OT-II)CBnel Tg(Trp53R172H)8512Jmr/J (Changed: 15-NOV-07 ) Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System See Colony Maintenance Species laboratory mouse Generation N10+N3 (25-JUN-09) Donating Investigator Brad Nelson, BC Cancer Agency Description
These compound transgenic mice carry a rat Erbb2/HER-2/neu oncogene tagged with ovalbumin epitopes OT-I and OT-II, which are recognized by T cell receptors, under the control of the MMTV promoter (termed fusion protein neuOT-I/OT-II). In addition, this strain carries a mouse Trp53 mini-gene, harboring a G to A point mutation in codon 172 (changing Arg to His; R172H) driven by the rat whey acidic protein promoter.Approximately 85% of compound mutant females develop focal mammary tumors at 6-10 months of age. Both virgin and breeder mice develop tumors. Approximately 37% of tumor-bearing mice develop metastatic disease to the lung. High expression of neu is detected in tumor tissue while very low levels are found in lung and ovary.
Female mice carrying only the neuOT-I/OT-II mutation develop focal mammary tumors at approximately 18 months of age.
This strain may be useful in studies of cancer immunotherapy.
Development
This compound mutant strain carries two independently-created transgenes that were later intercrossed. One construct/line was designed to tag T cell receptor-recognized ovalbumin epitopes SIINFEKL and ISQAVHAAHAEINEAGR with the rat Erbb2/HER-2/neu oncogene, creating a fusion protein under the control of an MMTV promoter (termed neuOT-I/OT-II). The vector was injected into C57BL/6 oocytes. Line C was selected for further studies based on mammary-specific expression and favorable tumor latency and frequency. This line was maintained on a C57BL/6 background. The second transgene contributes the rat whey acidic protein promoter driven mouse Trp53 mini-gene that carries a point mutation in codon 172 (CGC to CAC; Arg172His). This transgenic line was generated by microinjection into FVB mouse embryos and backcrossed to C57BL/6 for more than ten generations by the donating investigator. These independent transgenic strains were interbred to produce this bi-transgenic line.
Control Information
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying Tg(Trp53R172H)8512Jmr allele
002659 FVB/N-Tg(Trp53R172H)8512Jmr/J View Strains carrying Tg(Trp53R172H)8512Jmr (1 strain)
004301 129-Trp53tm1Holl/J 002080 129-Trp53tm1Tyj/J 008652 129S-Trp53tm2Tyj/J 008651 129S-Trp53tm3Tyj/J 008462 B6.129P2-Trp53tm1Brn/J 002101 B6.129S2-Trp53tm1Tyj/J 008183 B6.129S4(Cg)-Trp53tm2.1Tyj/J 008182 B6.129S4-Trp53tm3.1Tyj/J 007218 B6.129S6-Trp53tm2Xu/J 008045 B6;129-Trp53tm2Holl/J 006980 B6;129-Trp53tm2Xu/J 008191 B6;129S2-Trp53tm1Tyj Nf1tm1Tyj/J 002103 B6;129S2-Trp53tm1Tyj/J 008181 B6;129S4-Trp53tm4Tyj/J 008361 B6;129S4-Trp53tm5Tyj/J 002526 C.129S2(B6)-Trp53tm1Tyj/J 002547 C3Ou.129S2(B6)-Trp53tm1Tyj/J 002899 FVB.129S2(B6)-Trp53tm1Tyj/J 002660 FVB/N-Tg(Trp53R172L)4491Jmr/J 003262 STOCK Tg(Trp53A135V)L3Ber/J
002499 C57BL/6J-Tg(WapIGFBP3)67Dlr/J 002677 FVB.Cg-Tg(WapMyc)212Bri/J 002660 FVB/N-Tg(Trp53R172L)4491Jmr/J
004997 B6.Cg-Tg(MMTV-TGFBR2)7Hlm/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 002375 B6;D2-Tg(MMTVTGFB1)46Hlm/J 010576 B6;SJL-Tg(MMTV-rtTA)4-1Jek/J 002459 B6D2-Tg(MMTVTGFA)254Rjc/J 002373 B6D2-Tg(MMTVTGFA)29Rjc/J 002870 B6SJL-Tg(Wnt1)1Hev/J 005038 FVB-Tg(MMTV-Erbb2)NK1Mul/J 004363 FVB.Cg-Tg(MMTV-vHaras)SH1Led/J 002953 FVB.Cg-Tg(MMTVTGFA)254Rjc/J 002934 FVB.Cg-Tg(Wnt1)1Hev/J 002437 FVB/N-Tg(MMTV-Notch4)3Rnc/J 002374 FVB/N-Tg(MMTV-PyVT)634Mul/J 002376 FVB/N-Tg(MMTVneu)202Mul/J 002933 FVB/NJ-Tg(MMTVTGFB1)46Hlm/J 003690 STOCK Tg(MMTV-Cdc37)1Stp/J 003337 STOCK Tg(MMTV-PIP)1Shu/J 003551 STOCK Tg(MMTV-cre)1Mam/J 003553 STOCK Tg(MMTV-cre)4Mam/J
Phenotype
Phenotype Information
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Tg(MMTV-neu/OT-I/OT-II)CBnel/? Tg(Trp53R172H)8512Jmr/?
involves: C57BL/6 * FVB
- tumorigenesis
- mammary adenocarcinoma (MGI Ref ID J:122846)
- 80% of females develop adencarcinomas by 6-10 months of age; mice generally have 1or two tumors
- tumors are highly mitotic with glandular differentiation in ~30% of cases; ~90% of tumors have minimal necrosis
This mouse can be used to support research in many areas including:
Tcra relatedCancer Research
Increased Tumor Incidence
Mammary Gland Tumors
Mammary Gland Tumors: females only
Other Tissues/Organs: lung
Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Research Tools
Cancer Research
Tcrb relatedHematological Research
Immunological Defects
Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Immunodeficiency
Inflammation
T Cell Receptor Signaling Defects
Research Tools
Cancer Research
specific T cell deficiency
Trp53 relatedHematological Research
Immunological Defects
Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Immunodeficiency
Inflammation
T Cell Receptor Signaling Defects
Apoptosis Research
Endogenous Regulators
Cancer Research
Increased Tumor Incidence
Lymphomas
Other Tissues/Organs: osteosarcoma
Toxicology
Tumor Suppressor Genes
Immunology and Inflammation Research
Intracellular Signaling Molecules
Mouse/Human Gene Homologs
Li-Fraumeni syndrome
Research Tools
Toxicology Research
B and T cell deficiency, xenograft transplant host
drug/compound testing
Genes & Alleles
Gene & Allele Information
| Allele Symbol | Tg(MMTV-neu/OT-I/OT-II)CBnel | ||
|---|---|---|---|
| Allele Name | transgene insertion C, Brad Nelson | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | neuOT-I/OT-II; | ||
| Strain of Origin | C57BL/6 | ||
| Expressed Gene | Tcra, T-cell receptor alpha chain, mouse, laboratory | ||
| Expressed Gene | Tcrb, T-cell receptor beta chain, mouse, laboratory | ||
| Promoter | MMTV, Mouse Mammary Tumor Virus, MMTV | ||
| Molecular Note | The transgene construct was designed to tag T cell receptor-recognized ovalbumin epitopes SIIFEKL (CD8+, OT-1) and ISQAVHAAHAEINEAGR (CD4+, OT-II)with the rat Erbb2/HER-2/neu oncogene under the control of an MMTV promoter creating afusion protein (termed neuOT-I/OT-II). The vector was injected into C57BL/6 oocytes. Line C was selected for further studies based on mammary-specific expression and favorable tumor latency and frequency. [MGI Ref ID J:122846] | ||
| Allele Symbol | Tg(Trp53R172H)8512Jmr | ||
| Allele Name | transgene insertion 8512, Jeffrey Rosen | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | 172R-H; p53-172H; | ||
| Mutation Made By | Jeffrey Rosen, Baylor College of Medicine | ||
| Strain of Origin | FVB | ||
| Expressed Gene | Trp53, transformation related protein 53, mouse, laboratory | ||
| Promoter | Wap, whey acidic protein, rat | ||
| General Note | On an FVB/N background transgenic mice express TRP53 with both dominant-negative and a gain-of function properties. | ||
| Molecular Note | This transgene contains the rat whey acidic protein promoter and an allele of the mouse Trp53 mini-gene that carries a point mutation in codon 172 (CGC->CAC; Arg172His). [MGI Ref ID J:46426] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(MMTV-neu/OT-I/OT-II)CBnel, Standard PCR
Tg(Trp53R172H)8512Jmr, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References
Selected Reference(s)
Wall EM; Milne K; Martin ML; Watson PH; Theiss P; Nelson BH. 2007. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res 67(13):6442-50. [PubMed: 17616705] [MGI Ref ID J:122846]
Additional References
Tg(Trp53R172H)8512Jmr relatedChatterjee G; Rosner A; Han Y; Zelazny ET; Li B; Cardiff RD; Perkins AS. 2002. Acceleration of Mouse Mammary Tumor Virus-Induced Murine Mammary Tumorigenesis by a p53(172H) Transgene: Influence of FVB Background on Tumor Latency and Identification of Novel Sites of Proviral Insertion. Am J Pathol 161(6):2241-53. [PubMed: 12466138] [MGI Ref ID J:80272]
Hadsell DL; Murphy KL; Bonnette SG; Reece N; Laucirica R; Rosen JM. 2000. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 19(7):889-98. [PubMed: 10702797] [MGI Ref ID J:61037]
Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM. 1998. A transgenic mouse model for mammary carcinogenesis. Oncogene 16(8):997-1007. [PubMed: 9519874] [MGI Ref ID J:46426]
Li B; Rosen JM; McMenamin-Balano J; Muller WJ; Perkins AS. 1997. neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 17(6):3155-63. [PubMed: 9154814] [MGI Ref ID J:40336]
Pannellini T; Spadaro M; Di Carlo E; Ambrosino E; Iezzi M; Amici A; Lollini PL; Forni G; Cavallo F; Musiani P. 2006. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol 176(12):7695-703. [PubMed: 16751417] [MGI Ref ID J:115041]
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS. 2001. Cooperating Oncogenic Events in Murine Mammary Tumorigenesis: Assessment of ErbB2, Mutant p53, and Mouse Mammary Tumor Virus. Exp Mol Pathol 70(3):183-93. [PubMed: 11417997] [MGI Ref ID J:70644]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number AX11
Colony Maintenance
Breeding & Husbandry When maintained as a live colony hemizygotes (single or double mutant) may be bred. It is not know whether homozygotes are viable and fertile. Mating System See above Diet Information LabDiet® 5K52/5K67
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $300.70 Female or Male Hemizygous for Tg(MMTV-neu/OT-I/OT-II)CBnel, Hemizygous for Tg(Trp53R172H)8512Jmr
Pairs /Price (US dollars $) Pair Genotype $355.05 Noncarrier for Tg(MMTV-neu/OT-I/OT-II)CBnel, Noncarrier for Tg(Trp53R172H)8512Jmr x Hemizygous for Tg(MMTV-neu/OT-I/OT-II)CBnel, Hemizygous for Tg(Trp53R172H)8512Jmr
Additional Supply Details
| Pricing for International shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $391.00 Female or Male Hemizygous for Tg(MMTV-neu/OT-I/OT-II)CBnel, Hemizygous for Tg(Trp53R172H)8512Jmr
Pairs /Price (US dollars $) Pair Genotype $461.60 Noncarrier for Tg(MMTV-neu/OT-I/OT-II)CBnel, Noncarrier for Tg(Trp53R172H)8512Jmr x Hemizygous for Tg(MMTV-neu/OT-I/OT-II)CBnel, Hemizygous for Tg(Trp53R172H)8512Jmr
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of approximately nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within two business days following order placement. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
OncoMouse® requires a license from DuPont, see Licenses for Strains with OncoMouse® Technology.
For additional Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.